Advertisement

Organisation › Details
Ipsen (Group)
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology (adult & pediatric). Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. *
![]() |
Start | 2007-08-25 existent |
![]() |
Industry | pharmaceutical |
![]() |
Person | Meek, David (Ferring 202001– CEO of FerGene before Ipsen + Baxalta + Endocyte + Novartis + JnJ) |
Person 2 | le Chatelier, Aymeric (Ipsen 201603 CFO) | |
![]() |
Region | Paris |
Country | France | |
Street | 42 rue du Docteur Blanche | |
City | 75016 Paris | |
Tel | +33-1-443043-43 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | F: 1,001 to 5,000 (2017-02-23) |
Currency | EUR | |
Annual sales | 1,671,100,000 (revenues, consolidated (2016) 2016-12-31) | |
Profit | 226,600,000 (2016-12-31) | |
Cash | 425,500,000 (2016-12-31) | |
* Document for �About Section�: | ||
Record changed: 2021-04-05 |
Advertisement

More documents for Ipsen (Group)
- [1] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
- [2] Ipsen S.A.. (1/24/20). "Press Release: Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria". Paris....
- [3] Ipsen S.A.. (12/18/19). "Press Release: Ipsen Announces Departure of David Meek as Chief Executive Officer". Paris....
- [4] Ferring Pharmaceuticals S.A.. (12/18/19). "Press Release: FerGene Appoints David Meek Chief Executive Officer". Cambridge, MA....
- [5] Lysogene S.A.. (10/17/19). "Press Release: Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer". Paris....
- [6] Debiopharm International SA. (6/12/19). "Press Release: Debiopharm and Ipsen Extend Their Strategic Decapeptyl (triptorelin) Partnership for another 15 Years". Lausanne & Paris....
- [7] Genmab A/S. (3/11/19). "Press Release: Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations". Copenhagen....
- [8] 3B Pharmaceuticals GmbH. (11/20/18). "Press Release: Ipsen and 3BP Announce First Patient Dosed in Phase I/II Study for First-in-class Radionuclide (IPN01087)". Paris....
- [9] Ipsen S.A.. (11/15/18). "Press Release: European Commission Approves Ipsen’s Cabometyx (cabozantinib) for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib". Paris....
- [10] Uniqure N.V.. (6/13/18). "Press Release: Uniqure Announces New Appointments to its Board of Directors". Lexington, MA & Amsterdam....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
» top